Andrew Stephens
YOU?
Author Swipe
View article: Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning
Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning Open
INTRODUCTION The emergence, stability, and contributing factors of Alzheimer's disease (AD) gray matter subtypes remain unclear. METHODS We analyzed data from 1323 individuals without a diagnosis of dementia (CDR < 1) with T1w‐MRI and amyl…
View article: Ongoing Phase 3 Clinical Trial on the Efficacy of [18F] florbetaben PET for the Diagnosis of Cardiac AL Amyloidosis
Ongoing Phase 3 Clinical Trial on the Efficacy of [18F] florbetaben PET for the Diagnosis of Cardiac AL Amyloidosis Open
View article: Developing a novel reference region for [18F]PI-2620-PET imaging to facilitate the assessment of 4-repeat tauopathies
Developing a novel reference region for [18F]PI-2620-PET imaging to facilitate the assessment of 4-repeat tauopathies Open
View article: Utility, Costs and Cost‐Utility of Amyloid‐<scp>PET</scp> in the Diagnostic Process of Memory Clinic Patients: A Trial‐Based Economic Evaluation From <scp>AMYPAD</scp>‐<scp>DPMS</scp>
Utility, Costs and Cost‐Utility of Amyloid‐<span>PET</span> in the Diagnostic Process of Memory Clinic Patients: A Trial‐Based Economic Evaluation From <span>AMYPAD</span>‐<span>DPMS</span> Open
Background Amyloid positron emission tomography (PET) is instrumental in achieving an accurate diagnosis and may help to limit health‐seeking behavior. Currently, amyloid‐PET is not routinely used in clinical practice due to lack of eviden…
View article: Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study
Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study Open
View article: Amyloid PET predicts atrophy in older adults without dementia: Results from the AMYPAD Prognostic & Natural History Study
Amyloid PET predicts atrophy in older adults without dementia: Results from the AMYPAD Prognostic & Natural History Study Open
The impact of amyloid-β (Aβ) accumulation on regional brain atrophy in preclinical Alzheimer’s disease (AD), and its interaction with risk factors like sex and APOE -ε4 carriership, remains unclear. In this study, we examined these associa…
View article: Radiosynthesis, <i>In Vitro</i> Characterization, and <i>In Vivo</i> PET Neuroimaging of [<sup>18</sup>F]F-4 for Tau Protein: A First-in-Human PET Study
Radiosynthesis, <i>In Vitro</i> Characterization, and <i>In Vivo</i> PET Neuroimaging of [<sup>18</sup>F]F-4 for Tau Protein: A First-in-Human PET Study Open
[18F]PI-2620 is a promising radiopharmaceutical for positron emission tomography (PET) imaging of both Alzheimer's disease (AD) and non-Alzheimer's disease (non-AD) tauopathies in humans. An array of fluorinated derivatives of t…
View article: Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis
Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis Open
View article: Multi-parametric [18F]PI-2620 tau PET/MRI for the phenotyping of different Alzheimer’s disease variants
Multi-parametric [18F]PI-2620 tau PET/MRI for the phenotyping of different Alzheimer’s disease variants Open
Purpose Heterogeneity in clinical phenotypes has led to the description of different phenotypes of Alzheimer’s disease (AD). Besides the most frequent amnestic variant of AD (aAD), patients presenting with language deficits are diagnosed w…
View article: In Vivo Head-to-Head Comparison of [<sup>18</sup>F]GTP1 with [<sup>18</sup>F]MK-6240 and [<sup>18</sup>F]PI-2620 in Alzheimer Disease
In Vivo Head-to-Head Comparison of [<sup>18</sup>F]GTP1 with [<sup>18</sup>F]MK-6240 and [<sup>18</sup>F]PI-2620 in Alzheimer Disease Open
Alzheimer disease (AD) is characterized by the accumulation of tau neurofibrillary tangles that can be labeled with PET tracers. Multiple tau PET tracers have been used in clinical studies, including [18F]GTP1, [18F]P…
View article: Demographic Analysis of PROMIS Responders vs. Non-Responders
Demographic Analysis of PROMIS Responders vs. Non-Responders Open
View article: Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET—A Decade of Post-Authorization Insights
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET—A Decade of Post-Authorization Insights Open
Florbetaben (FBB) is a radiopharmaceutical approved by the FDA and EMA in 2014 for the positron emission tomography (PET) imaging of brain amyloid deposition in patients with cognitive impairment who are being evaluated for Alzheimer’s dis…
View article: Image‐derived phenotypes in the AMYPAD Prognostic and Natural History Study
Image‐derived phenotypes in the AMYPAD Prognostic and Natural History Study Open
Background The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic & Natural History Study (PNHS) is a prospective longitudinal PET cohort of over 1,500 non‐demented individuals from 10 parent cohorts across Europe. We provi…
View article: Differential network‐based propagation of cortical thinning in atrophy subtypes in non‐demented individuals
Differential network‐based propagation of cortical thinning in atrophy subtypes in non‐demented individuals Open
Background Different patterns of atrophy exist in the dementia stage of AD. However, little is known about the heterogeneity of atrophy patterns and the mechanisms that drive subsequent propagation of the disease in the preclinical stages.…
View article: Multimodal phenotyping of successful cognitive aging
Multimodal phenotyping of successful cognitive aging Open
Background While some memory decline in old age is “normal”, there are some older individuals with maintained high cognitive performance. Using a multimodal approach including neuroimaging, fitness, genetic and questionnaire data (Fig1A), …
View article: From AMYPAD to Euro‐PAD: creating a multi‐cohort preclinical database to model onset of Alzheimer’s disease
From AMYPAD to Euro‐PAD: creating a multi‐cohort preclinical database to model onset of Alzheimer’s disease Open
Background The emergence of disease‐modifying drug therapies is expected to revolutionize the field of Alzheimer's disease (AD). Recent results from anti‐amyloid clinical trials highlight the importance of early identification and accurate…
View article: Image‐derived phenotypes in the AMYPAD Prognostic and Natural History Study
Image‐derived phenotypes in the AMYPAD Prognostic and Natural History Study Open
Background The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic & Natural History Study (PNHS) is a prospective longitudinal PET cohort of over 1,500 non‐demented individuals from 10 parent cohorts across Europe. We provi…
View article: Multimodal phenotyping of successful cognitive aging
Multimodal phenotyping of successful cognitive aging Open
Background While some memory decline in old age is “normal”, there are some older individuals with maintained high cognitive performance. Using a multimodal approach including neuroimaging, fitness, genetic and questionnaire data (Figure 1…
View article: The Centiloid scale: guidance on clinical context of use from the AMYPAD Consortium
The Centiloid scale: guidance on clinical context of use from the AMYPAD Consortium Open
Background The Centiloid method (CL) was introduced as a tracer‐independent measure for cortical amyloid load and is now commonly used in Alzheimer’s disease (AD) clinical trials. To facilitate its implementation into clinical settings, th…
View article: Differential network‐based propagation of cortical thinning in atrophy subtypes in non‐demented individuals
Differential network‐based propagation of cortical thinning in atrophy subtypes in non‐demented individuals Open
Background Different patterns of atrophy exist in the dementia stage of AD. However, little is known about the heterogeneity of atrophy patterns and the mechanisms that drive subsequent propagation of the disease in the preclinical stages.…
View article: Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort
Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort Open
View article: Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium
Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium Open
Amyloid‐PET quantification through the tracer‐independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid‐β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to…
View article: Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study
Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study Open
Several studies have demonstrated strong agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support assessment by less experienced readers or in challenging cases. Howev…
View article: Qualitative and quantitative analysis of 18F-GP1 positron emission tomography in thrombotic cardiovascular disease
Qualitative and quantitative analysis of 18F-GP1 positron emission tomography in thrombotic cardiovascular disease Open
18 F-GP1 is a novel highly specific radiotracer that binds to activated platelets and thrombus. We aimed to establish the observer repeatability of coronary, carotid and cerebral 18 F-GP1 uptake in patients presenting with acute myocardial…
View article: Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model Open
INTRODUCTION Tau‐positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer properties, instr…
View article: Neuroinflammation Parallels <scp>18F</scp>‐<scp>PI</scp>‐2620 Positron Emission Tomography Patterns in Primary 4‐Repeat Tauopathies
Neuroinflammation Parallels <span>18F</span>‐<span>PI</span>‐2620 Positron Emission Tomography Patterns in Primary 4‐Repeat Tauopathies Open
Background Preclinical, postmortem, and positron emission tomography (PET) imaging studies have pointed to neuroinflammation as a key pathophysiological hallmark in primary 4‐repeat (4R) tauopathies and its role in accelerating disease pro…
View article: Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology
Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology Open
INTRODUCTION Assessing the potential sources of bias and variability of the Centiloid (CL) scale is fundamental for its appropriate clinical application. METHODS We included 533 participants from AMYloid imaging to Prevent Alzheimer's Dise…
View article: Amyloid-PET imaging predicts functional decline in clinically normal individuals
Amyloid-PET imaging predicts functional decline in clinically normal individuals Open
View article: Quantification supports amyloid-PET visual assessment of challenging cases: results from the AMYPAD-DPMS study
Quantification supports amyloid-PET visual assessment of challenging cases: results from the AMYPAD-DPMS study Open
Several studies have demonstrated the high agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support the assessment of less experienced readers and/or in challenging ca…
View article: Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [<sup>18</sup>F]PI-2620
Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [<sup>18</sup>F]PI-2620 Open
We used a new data-driven methodology to identify a set of reference regions that enhanced the quantification of the SUV ratio of the second-generation tau tracer 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridin…